Read by QxMD icon Read

Journal of Hepatology

Libin Deng, Wang Jiang, Xiaoning Wang, Andreas Merz, Marie-Sophie Hiet, Yujie Chen, Xiaoyu Pan, Yaming Jiu, Yu Yang, Bowen Yu, Yongnin He, Zhengkun Tu, Junqi Niu, Ralf Bartenschlager, Gang Long
BACKGROUND & AIMS: Hepatitis C virus (HCV) is a major cause of chronic liver disease, infecting approximately 71 million people worldwide. Assembly of infectious HCV particles involves host lipoproteins, giving rise to unique lipo-viro-particles (LVPs), but proteome studies suggest that additional cellular proteins are associated with HCV virions or other particles containing the viral envelope glycoprotein E2. Many of these host cell proteins are common markers of exosomes, most notably the intracellular adaptor protein syntenin required exosome biogenesis...
March 14, 2019: Journal of Hepatology
Juan Bayo, Esteban J Fiore, Luciana M Dominguez, Alejandrina Real, Mariana Malvicini, Manglio Rizzo, Catalina Atorrasagasti, Mariana G García, Josepmaria Argemi, Elisabeth D Martinez, Guillermo D Mazzolini
BACKGROUND AND AIMS: A causal link has recently been established between epigenetic alterations and hepatocarcinogenesis, indicating that epigenetic inhibition may have therapeutic potential. We aimed to identify and target epigenetic modifiers that show molecular alterations in hepatocellular carcinoma (HCC). METHODS: We studied the molecular-clinical correlations of epigenetic modifiers including bromodomains, histone acetyltransferases, lysine methyltransferases and lysine demethylases in HCC using the Cancer Genome Atlas (TCGA) data of 365 HCC...
March 14, 2019: Journal of Hepatology
Arianna Pocaterra, Giulia Santinon, Patrizia Romani, Irene Brian, Andrea Dimitracopoulos, Andrea Ghisleni, Alejandro Carnicer-Lombarte, Mattia Forcato, Paola Braghetta, Marco Montagner, Francesca Galuppini, Mariaceleste Aragona, Gianmaria Pennelli, Silvio Bicciato, Nils Gauthier, Kristian Franze, Sirio Dupont
BACKGROUND & AIMS: In vitro, several data indicate that cell function can be regulated by the mechanical properties of cells and of the microenvironment. Cells measure these features by developing forces via their actomyosin cytoskeleton, and respond accordingly by transducing forces into biochemical signals that instruct cell behavior. Among these, the transcriptional coactivators YAP/TAZ recently emerged as key factors mediating multiple responses to actomyosin contractility. However, whether mechanical cues regulate adult liver tissue homeostasis, and whether this occurs through YAP/TAZ, remains largely unaddressed...
March 13, 2019: Journal of Hepatology
Hui Feng, Anna-Lena Sander, Andrés Moreira-Soto, Daisuke Yamane, Jan Felix Drexler, Stanley M Lemon
BACKGROUND & AIMS: Unlike other hepatitis viruses that have infected primates for millions of years, hepatitis A virus (HAV) likely entered human populations only 10-12 thousand years ago after jumping from a rodent host. The phylogeny of modern hepatoviruses infecting rodents and bats suggest multiple similar host shifts have occurred in the past. The factors determining such shifts are unknown, but the capacity to overcome innate antiviral responses in a foreign species is likely key...
March 12, 2019: Journal of Hepatology
Young-Suk Lim, Geum-Youn Gwak, Jonggi Choi, Yung Sang Lee, Kwan Soo Byun, Yoon Jun Kim, Byung Chul Yoo, So Young Kwon, Han Chu Lee
BACKGROUND AND AIMS: Tenofovir disoproxil fumarate (TDF) monotherapy has displayed non-inferior efficacy compared with TDF plus entecavir (ETV) combination therapy in patients with hepatitis B virus (HBV) resistant to ETV and/or adefovir (ADV). Nonetheless, the virologic response rate was suboptimal up to 144 weeks of TDF monotherapy with uncertain long-term safety. METHODS: One trial enrolled patients with ETV resistance without ADV resistance (n=90), and another trial included patients with ADV resistance (n=102)...
March 12, 2019: Journal of Hepatology
Xun Xu, Hai-Long Zhang, Qiu-Ping Liu, Shu-Wen Sun, Jing Zhang, Fei-Peng Zhu, Guang Yang, Xu Yan, Yu-Dong Zhang, Xi-Sheng Liu
BACKGROUND & AIMS: Microvascular invasion (MVI) impairs surgical outcomes in hepatocellular carcinoma (HCC) patients. As a single highly reliable factor to preoperatively predict MVI is lacking, we developed a computational approach integrating large-scale clinical and imaging modalities, especially radiomic features from contrast-enhanced CT, to predict MVI and clinical outcomes in HCC patients. METHODS: In total, 495 surgically resected patients were retrospectively included...
March 12, 2019: Journal of Hepatology
Vandana Jain, Charlotte Burford, Emma C Alexander, Harry Sutton, Anil Dhawan, Deepak Joshi, Mark Davenport, Nigel Heaton, Nedim Hadzic, Marianne Samyn
BACKGROUND & AIMS: Native liver survival (NLS) for Biliary Atresia (BA) into adulthood, has been reported as 14-44% worldwide. Complications related to portal hypertension (PHT) and cholangitis are common in adulthood. For those requiring liver transplantation (LT), the timing can be challenging. The aim of the study, was to identify potential predictor variables, for young people (YP) with BA, requiring LT after 16 years of age. METHODS: Single-centre retrospective analysis of 397 patients, who underwent Kasai Portoenterostomy (KP) between 1980-96, at our centre...
March 12, 2019: Journal of Hepatology
Tiffany Cho-Lam Wong, James Yan-Yue Fung, Tracy Yu-Shi Cui, Allan Hoi-Kin Lam, Jeff Wing-Chiu Dai, Albert Chi-Yan Chan, Tan-To Cheung, Kenneth Siu-Ho Chok, Kelvin Kwok-Chai Ng, Chung-Mau Lo
BACKGROUND: The impact of hepatitis B core antibody (anti-HBc) positive liver grafts on survival and risk of de novo hepatitis B (HBV) infection after liver transplantation (LT) remains controversial. METHODS: This was a retrospective study that included all adult LT recipients from 2000 to 2015. Data was retrieved from a prospectively collected database. Antiviral monotherapy prophylaxis was given for anti-HBc positive group. RESULTS: There were 964 LT during study period, which included 416(43...
March 11, 2019: Journal of Hepatology
Jia Xiao, Fei Wang, Nai-Kei Wong, Jinhan He, Rui Zhang, Ruijuan Sun, Yanying Xu, Yingxia Liu, Wei Li, Kazuo Koike, Weiling He, Hong You, Yinglei Miao, Xiaowei Liu, Mingming Meng, Bin Gao, Hua Wang, Cui Li
Liver diseases affect millions of people worldwide. In most developed countries, the incidence of viral hepatitis is waning as a result of modern advances in disease prevention, diagnosis, and therapies. Expanded programs for systematic immunization against hepatitis B virus (HBV) have also significantly brought down the number of new cases in many countries, including China. In contrast, with the improvement of living standards, prevalence of metabolic liver diseases, including non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) is set to rise, which ultimately leads to more cases of end-stage liver diseases (liver failure, cirrhosis, and liver cancer)...
March 11, 2019: Journal of Hepatology
Hélène Fontaine, Laurent Alric, Julien Labreuche, Benjamin Legendre, Alexandre Louvet, Corinne Antoine, Christophe M Legendre, Marc Hazzan, Nassim Kamar, Sebastien Dharancy, Stanislas Pol, Alain Duhamel, Philippe Mathurin
BACKGROUND & AIMS: Before antiviral therapy, kidney transplant recipients infected with hepatitis B virus (HBV) or hepatitis C virus (HCV) had poor outcomes. Since the 90s, nucleos(t)ide analogues have been widely used in HBV-infected patients, while interferon-based therapy was rarely used in HCV-infected patients. The aim of this study was to assess the impact of HBV and HCV on patient and graft survival, according to viral replication status. METHODS: Data from January 1993 to December 2010 were extracted from the French national database CRISTAL...
March 9, 2019: Journal of Hepatology
V Paradis, A Quaglia
No abstract text is available yet for this article.
March 8, 2019: Journal of Hepatology
Vinay Sundaram
No abstract text is available yet for this article.
March 8, 2019: Journal of Hepatology
David Wyles, Ola Weiland, Betty Yao, Frank Weilert, Jean-Francois Dufour, Stuart C Gordon, Albrecht Stoehr, Ashley Brown, Stefan Mauss, Zhenzhen Zhang, Tami Pilot-Matias, Lino Rodrigues, Federico J Mensa, Fred Poordad
No abstract text is available yet for this article.
March 8, 2019: Journal of Hepatology
Juan Macías, Luis E Morano, Francisco Téllez, Rafael Granados, Antonio Rivero-Juárez, Rosario Palacios, MaJosé Ríos, Dolores Merino, Montserrat Pérez-Pérez, Antonio Collado, Blanca Figueruela, Aitana Morano, Carolina Freyre-Carrillo, José M Martín, Antonio Rivero, Federico García, Juan A Pineda
BACKGROUND & AIMS: Persons who have ever injected drugs (PWID) on opiate agonist therapy (OAT) might have lower adherence to direct antiviral agents against HCV (DAA) and, therefore, lower rates of sustained viral response (SVR). Because of this, we compared the SVR rates to interferon-free DAA combinations among individuals with and without OAT in real-world. METHODS: The HEPAVIR-DAA cohort, recruiting HIV/HCV-coinfected patients (NCT02057003), and the GEHEP-MONO cohort (NCT02333292), including HCV-monoinfected individuals, are ongoing prospective multicenter cohorts of patients receiving DAA in clinical practice...
March 7, 2019: Journal of Hepatology
Ruben Hernaez, Jennifer R Kramer, Yan Liu, Fasiha Kanwal
No abstract text is available yet for this article.
March 5, 2019: Journal of Hepatology
Fabio Ferla, Andrea Lauterio, Riccardo De Carlis, Stefano Di Sandro, Niccolò Petrucciani, Laura Benuzzi, Luciano De Carlis
No abstract text is available yet for this article.
March 2, 2019: Journal of Hepatology
Louise J M Alferink, Sarwa Darwish Murad
No abstract text is available yet for this article.
March 2, 2019: Journal of Hepatology
Vincent Wai-Sun Wong, Henry Lik-Yuen Chan
No abstract text is available yet for this article.
March 2, 2019: Journal of Hepatology
Claire Francoz, Elsa Sola
No abstract text is available yet for this article.
March 1, 2019: Journal of Hepatology
Felix Johannes Jacobi, Katharina Wild, Maike Smits, Katharina Zoldan, Benedikt Csernalabics, Tobias Flecken, Julia Lang, Philipp Ehrenmann, Florian Emmerich, Maike Hofmann, Robert Thimme, Christoph Neumann-Haefelin, Tobias Boettler
BACKGROUND & AIMS: Current antiviral therapies lack the potential to eliminate persistent HBV infection. HBV-specific T cells are crucial for HBV control and have recently been shown to be protective in patients following discontinuation of antiviral therapy. Thus, T cell-based approaches may greatly improve the therapeutic landscape of HBV-infection. We aimed to augment HBV-specific CD4 T cells from chronically infected patients by targeting different immunological pathways. METHODS: Expression of various co-stimulatory and inhibitory receptors on HBV- and Influenza-specific CD4 T cells was analyzed directly ex vivo by MHC class II-tetramers...
February 28, 2019: Journal of Hepatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"